论文部分内容阅读
目的探讨α-硫辛酸联合依帕司他治疗2型糖尿病周围神经病变的临床疗效。方法选取2012年1月—2013年2月百色市田阳县人民医院收治的2型糖尿病周围神经病变患者87例,按入院先后顺序分为A、B、C组,各29例。A组患者予以α-硫辛酸联合依帕司他治疗,B组患者予以α-硫辛酸治疗,C组患者予以依帕司他治疗。观察3组患者临床疗效、治疗前后多伦多临床评分系统(TCSS)评分、临床症状评分系统(TSS)评分、神经传导速度(腓总神经感觉传导速度、腓总神经运动传导速度)及不良反应发生情况。结果 A组患者总有效率高于B、C组,差异有统计学意义(P<0.05);B、C组患者临床疗效比较,差异无统计学意义(P>0.05)。治疗后A组患者TCSS评分、TSS评分低于B、C组,差异有统计学意义(P<0.05);B、C组患者TCSS评分、TSS评分比较,差异无统计学意义(P>0.05);3组患者治疗后TCSS评分、TSS评分低于治疗前,差异有统计学意义(P<0.05)。治疗后A组患者腓总神经感觉传导速度、腓总神经运动传导速度高于B、C组,差异有统计学意义(P<0.05);B、C组患者腓总神经感觉传导速度、腓总神经运动传导速度比较,差异无统计学意义(P>0.05);3组患者治疗后腓总神经感觉传导速度、腓总神经运动传导速度高于治疗前,差异有统计学意义(P<0.05)。3组患者均未发生严重不良反应。结论α-硫辛酸联合依帕司他治疗2型糖尿病周围神经病变的临床疗效显著,可改善患者临床症状及神经传导速度,且不良反应少。
Objective To investigate the clinical efficacy of α-lipoic acid combined with epalrestat in the treatment of type 2 diabetic peripheral neuropathy. Methods A total of 87 patients with type 2 diabetic peripheral neuropathy admitted from January 2012 to February 2013 in Tianyang County People’s Hospital of Baise City were selected and divided into groups A, B and C, with 29 cases in each group. Patients in group A were given α-lipoic acid combined with epalrestat, patients in group B were treated with α-lipoic acid, and patients in group C were treated with epalrestat. The clinical efficacy, clinical score system (TCSS) score, clinical symptom score system (TSS) score, nerve conduction velocity (peroneal nerve sensory conduction velocity and peroneal nerve conduction velocity) and adverse reactions in the three groups were observed before and after treatment. . Results The total effective rate of group A was higher than that of group B and C (P <0.05). There was no significant difference in clinical curative effect between group B and C (P> 0.05). After treatment, TCSS score and TSS score in group A were lower than those in group B and C (P <0.05). There was no significant difference in TCSS score and TSS score between group B and C (P> 0.05) The TCSS score and TSS score of the three groups after treatment were lower than those before treatment, the difference was statistically significant (P <0.05). After treatment, the sensory velocity of peroneal nerve and the velocity of peroneal nerve movement in group A were higher than those in group B and C (P <0.05); The sensory rate of peroneal nerve sensory conduction, There was no significant difference in nerve conduction velocity between the two groups (P> 0.05). The sensory nerve conduction velocity and common motor nerve conduction velocity in the three groups were significantly higher than those before treatment (P <0.05) . No serious adverse reactions occurred in all three groups. Conclusion The clinical efficacy of α-lipoic acid combined with epalrestat in the treatment of type 2 diabetic peripheral neuropathy is significant, which can improve the clinical symptoms and nerve conduction velocity of patients with less adverse reactions.